[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wild-type-transthyretin-cardiac-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wild-type-transthyretin-cardiac-amyloidosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100492877","long-term-follow-up-ltfu-of-subjects-dosed-with-ntla-2001-100492877",false,"NCT05697861","Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001","Long-Term Follow-Up of Subjects Treated With NTLA-2001","Inclusion Criteria:\n\n1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.\n2. A subject has provided informed consent for the LTFU study.\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":19,"type":20},72,"ESTIMATED","OBSERVATIONAL","This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.",[24,25,26],"Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy","Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy","Wild-Type Transthyretin Cardiac Amyloidosis","RECRUITING","2025-08-20",{"date":30,"type":31},"2025-08-26","ACTUAL",{"date":33,"type":31},"2023-07-10",{"date":35,"type":20},"2038-03",{"name":37,"class":38},"Intellia Therapeutics","INDUSTRY",4]